These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 22822914)
21. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
22. Computational systems approach for drug target discovery. Chandra N Expert Opin Drug Discov; 2009 Dec; 4(12):1221-36. PubMed ID: 23480463 [TBL] [Abstract][Full Text] [Related]
23. New screens and targets in antibacterial drug discovery. Falconer SB; Brown ED Curr Opin Microbiol; 2009 Oct; 12(5):497-504. PubMed ID: 19651534 [TBL] [Abstract][Full Text] [Related]
25. Advances and strategies in discovery of new antibacterials for combating metabolically resting bacteria. Bald D; Koul A Drug Discov Today; 2013 Mar; 18(5-6):250-5. PubMed ID: 23032727 [TBL] [Abstract][Full Text] [Related]
26. Postgenomic strategies in antibacterial drug discovery. Brötz-Oesterhelt H; Sass P Future Microbiol; 2010 Oct; 5(10):1553-79. PubMed ID: 21073314 [TBL] [Abstract][Full Text] [Related]
27. New strategies for antibacterial drug design: targeting non-multiplying latent bacteria. Coates AR; Hu Y Drugs R D; 2006; 7(3):133-51. PubMed ID: 16752940 [TBL] [Abstract][Full Text] [Related]
28. Discovery of estrogen receptor modulators: a review of virtual screening and SAR efforts. Xu X; Yang W; Li Y; Wang Y Expert Opin Drug Discov; 2010 Jan; 5(1):21-31. PubMed ID: 22823969 [TBL] [Abstract][Full Text] [Related]
29. Cancer Drug Development: New Targets for Cancer Treatment. Curt GA Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987 [TBL] [Abstract][Full Text] [Related]
31. When analoging is not enough: scaffold discovery in medicinal chemistry. Zhao H; Akritopoulou-Zanze I Expert Opin Drug Discov; 2010 Feb; 5(2):123-34. PubMed ID: 22822912 [TBL] [Abstract][Full Text] [Related]
32. Advances in LC platforms for drug discovery. Nicoli R; Martel S; Rudaz S; Wolfender JL; Veuthey JL; Carrupt PA; Guillarme D Expert Opin Drug Discov; 2010 May; 5(5):475-89. PubMed ID: 22823131 [TBL] [Abstract][Full Text] [Related]
33. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads. Bergsdorf C; Ottl J Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747 [TBL] [Abstract][Full Text] [Related]
34. Design of chemical libraries for screening. Villar HO; Hansen MR Expert Opin Drug Discov; 2009 Dec; 4(12):1215-20. PubMed ID: 23480462 [TBL] [Abstract][Full Text] [Related]
35. Chapter 1. Approaches to discovering novel antibacterial and antifungal agents. Donadio S; Monciardini P; Sosio M Methods Enzymol; 2009; 458():3-28. PubMed ID: 19374977 [TBL] [Abstract][Full Text] [Related]
37. What does systems biology mean for biomarker discovery? Azuaje F Expert Opin Med Diagn; 2010 Jan; 4(1):1-10. PubMed ID: 23496106 [TBL] [Abstract][Full Text] [Related]
38. Use of phage display technology for the determination of the targets for small-molecule therapeutics. Takakusagi Y; Takakusagi K; Sugawara F; Sakaguchi K Expert Opin Drug Discov; 2010 Apr; 5(4):361-89. PubMed ID: 22823088 [TBL] [Abstract][Full Text] [Related]
39. Tigecycline: a case study. Loh E; Ellis-Grosse E; Petersen PJ; Sum PE; Projan S Expert Opin Drug Discov; 2007 Mar; 2(3):403-18. PubMed ID: 23484649 [TBL] [Abstract][Full Text] [Related]
40. New concepts, experimental approaches, and dereplication strategies for the discovery of novel phytoestrogens from natural sources. Michel T; Halabalaki M; Skaltsounis AL Planta Med; 2013 May; 79(7):514-32. PubMed ID: 23479392 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]